References

London: BMJ Group and Pharmaceutical Press; 2012
Technology Appraisal guidance 182: Acute coronary syndrome – prasugrel: understanding NICE guidance.London: NICE; 2009
Technology Appraisal guidance 236: Ticagrelor for the treatment of acute coronary syndromes.London: NICE; 2011
Clinical guideline 94: Unstable Angina and NSTEMI.London: NICE; 2010
North West Medicines Information Centre. http://www.nelm.nhs.uk
Burger W, Chemnitius JM, Kneissl GD, Rücker G Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. J Intern Med. 2005; 257:(5)399-414
Keeling D, Baglin T, Tait C Guidelines on oral anticoagulation with warfarin. Br J Haematol. 2011; 153:(3)311-324
Perry DJ, Noakes TJC, Helliwell PS Guidelines for the management of patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007; 203:389-393
Scully C, Wolff A Oral surgery in patients on anticoagulant therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94:57-64
North West Medicines Information Centre. Surgical management of the primary care dental patient on warfarin. http://www.nelm.nhs.uk
Gomez-Moreno G, Aguilar-Salvatierra A, Martin-Piedra MA Dabigatran and rivaroxaban, new oral anticoagulants, new approaches in Dentistry. J Clin Exp Dent. 2010; 2:(1)e14-18
Technology Appraisal guidance 157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults.London: NICE; 2008
Technology Appraisal guidance 249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation.London: NICE; 2012
Electronic medicines compendium UK. Dabigatran etexilate (Pradaxa). http://www.medicines.org.uk/EMC/medicine/24839/SPC/Pradaxa+150+mg+hard+capsules (Accessed 14/08/2012)
Advice sheet sent to dentists regarding dabigatran etexilate. 2012;
Constable S, Winstanley P, Walley T, 3rd edition. Oxford: Elsevier Limited; 2007
Greenwood M, Meechan JG, Bryant D General medicine and surgery for dental practitioners: Part 7: Renal disorders. Br Dent J. 2003; 193:(4)181-184
Greenwood M, Seymour RA, Meechan JGOxford: Wiley-Blackwell; 2009

Haemostasis part 2: medications that affect haemostasis

From Volume 41, Issue 5, June 2014 | Pages 395-405

Authors

Neal J McCormick

BDS(Lpool), MFDS RCPS(Glasg)

General Professional Trainee (GPT), Health Education North East

Articles by Neal J McCormick

Undrell J Moore

BDS, PhD, FDS RCS(Eng)

Senior Lecturer in Oral Surgery, Newcastle Dental Hospital, Richardson Road, Newcastle Upon Tyne, NE2 4AZ, UK

Articles by Undrell J Moore

John G Meechan

BDS, PhD, FDS RCS(Eng), FDS RCS(Ed), FDS RCPS

Senior Lecturer, School of Dental Sciences, Newcastle University, Framlington Place, Newcastle uponTyne, NE2 4BW, UK

Articles by John G Meechan

Mohsen Norouzi

MD, MRCP(UK)

Specialist Registrar in Haematology, Royal Victoria Infirmary, Newcastle upon Tyne (Health Education North East), UK

Articles by Mohsen Norouzi

Abstract

Post-operative haemorrhage is a recognized complication in dental practice. This may be more prevalent in patients taking anti-thrombotic medications. It is important that the dentist understands the mechanism of action of these drugs and how they may affect management of dental patients.

Clinical Relevance: Dental professionals must be aware of those medications affecting haemostasis and how they may impact on management. The emergence of different therapeutic regimens has increased the number of such drugs.

Article

For many years, warfarin has been the most commonly used oral anticoagulant in the United Kingdom; however, as a long term medication it has disadvantages. This has led to the introduction of a number of new anticoagulant regimens that can impact on dental practice. Other medications, such as aspirin, are also used regularly for their anti-thrombotic effect. A clear understanding of oral anticoagulant therapy and the indications for treatment provision or suitable referral is important.

Prescribed medications are used to reduce the risk of a thrombo-embolic event. A thrombus is most likely to occur within a damaged vessel or heart wall. The pathologist Rudolph Virchow adopted a triad of risk factors for thrombo-embolism (Figure 1). These include:

The prevention and treatment of thrombo-embolism is the main indication for anticoagulant use. Table 1 shows the most common examples.

Some consideration should be given to the action of the different therapies available. They can be split into 3 main categories according to their action:

Register now to continue reading

Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Up to 2 free articles per month
  • New content available